PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
149.60%
Cash & equivalents growing 149.60% while GNPX's declined -61.17%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
149.60%
Below half of GNPX's -61.17%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.42%
Below half of GNPX's -50.62%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
835.01%
Higher PP&E (Net) Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1079.37%
Below half of GNPX's -4.04%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Below half of GNPX's -36.31%. Michael Burry sees a potential red flag for stagnation or capital shortage.
69.91%
Less than half of GNPX's -38.99%. David Dodd sees a more disciplined AP approach or lower volume.
-41.82%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-49.13%
Less than half of GNPX's 144.34%. David Dodd sees fewer expansions in other current obligations.
-44.50%
Less than half of GNPX's 13.75%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-44.50%
Less than half of GNPX's 13.75%. David Dodd sees far fewer liability expansions relative to competitor.
7.98%
Less than half of GNPX's 37.22%. David Dodd sees fewer share issuances vs. competitor.
4.22%
Below half GNPX's -2.94%. Michael Burry suspects major net losses or high dividends vs. competitor.
-271.57%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
132.15%
Below half GNPX's -64.03%. Michael Burry sees potential underperformance in building shareholder capital.
135.47%
Below half GNPX's -36.31%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-41.82%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
-152.72%
Less than half of GNPX's 61.17%. David Dodd sees better deleveraging or stronger cash buildup than competitor.